Margot Lo Pinto

Ms. Margot Lo Pinto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NGNima Rabienezhad Ganji
Nima Rabienezhad Ganji
Ornella UrzìOrnella Urzì
Ornella Urzì
VTVincenza Tinnirello
Vincenza Tinnirello
ECElisa Costanzo
Elisa Costanzo
GPGiulia Polito
Giulia Polito
Riccardo AlessandroRiccardo Alessandro
Riccardo Alessandro
In the last years, the field of nanomedicine and drug delivery has grown exponentially, providing new platforms to carry therapeutic agents into the target sites. Extracellular vesicles (EVs) are ready-to-use, biocompatible, and non-toxic nanoparticles that are revolutionizing the field of drug delivery. EVs are involved in cell–cell communication and mediate many physiological and pathological processes by transferring their bioactive cargo to target cells. Recently, nanovesicles from plants (PDNVs) are raising the interest of the scientific community due to their high yield and biocompatibility. This study aims to evaluate whether PDNVs may be used as drug delivery systems. We isolated and characterized nanovesicles from tangerine juice (TNVs) that were comparable to mammalian EVs in size and morphology. TNVs carry the traditional EV marker HSP70 and, as demonstrated by metabolomic analysis, contain flavonoids, organic acids, and limonoids. TNVs were loaded with DDHD1-siRNA through electroporation, obtaining a loading efficiency of 13%. We found that the DDHD1-siRNA complex TNVs were able to deliver DDHD1-siRNA to human colorectal cancer cells, inhibiting the target expression by about 60%. This study represents a proof of concept for the use of PDNVs as vehicles of RNA interference (RNAi) toward mammalian cells.

12 March 2025 in Materials
Verified
Journal Article
Open access
PDF file
VCVIVIANA COSTA
VIVIANA COSTA
LRLavinia Raimondi
Lavinia Raimondi
Simone D. ScilabraSimone D. Scilabra
Simone D. Scilabra
MPMargot Lo Pinto
Margot Lo Pinto
Daniele BellaviaDaniele Bellavia
Daniele Bellavia
Gianluca GiavaresiGianluca Giavaresi
Gianluca Giavaresi
An Mg-based alloy device manufactured via a superplastic forming process (Mg-AZ31+SPF) and coated using a hydrothermal method (Mg AZ31+SPF+HT) was investigated as a method to increase mechanical and osteointegration capability. The cell viability and osteointegrative properties of alloy-derived Mg AZ31+SPF and Mg AZ31+SPF+HT extracts were investigated regarding their effect on human mesenchymal stem cells (hMSCs) (maintained in basal (BM) and osteogenic medium (OM)) after 7 and 14 days of treatment. The viability was analyzed through metabolic activity and double-strand DNA quantification, while the osteoinductive effects were evaluated through qRT-PCR, osteoimage, and BioPlex investigations. Finally, a preliminary liquid mass spectrometry analysis was conducted on the secretome of hMSCs. Biocompatibility analysis revealed no toxic effect on cells’ viability or proliferation during the experimental period. A modulation effect was observed on the osteoblast pre-commitment genes of hMSCs treated with Mg-AZ31+SPF+HT in OM, which was supported by mineralization nodule analysis. A preliminary mass spectrometry investigation highlighted the modulation of protein clusters involved in extracellular exosomes, Hippo, and the lipid metabolism process. In conclusion, our results revealed that the Mg AZ31+SPF+HT extracts can modulate the canonical and non-canonical osteogenic process in vitro, suggesting their possible application in bone tissue engineering.

9 October 2024 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
SBSimone Bonelli
Simone Bonelli
MPMargot Lo Pinto
Margot Lo Pinto
YYYihong Ye
Yihong Ye
SMStephan A. Müller
Stephan A. Müller
SLStefan F. Lichtenthaler
Stefan F. Lichtenthaler
Simone D. ScilabraSimone D. Scilabra
Simone D. Scilabra
Ubiquitin carboxyl-terminal hydrolase 19 (USP19) is a unique deubiquitinase, characterized by multiple variants generated by alternative splicing. Several variants bear a C-terminal transmembrane domain that anchors them to the endoplasmic reticulum. Other than regulating protein stability by preventing proteasome degradation, USP19 has been reported to rescue substrates from endoplasmic reticulum-associated protein degradation in a catalytic-independent manner, promote autophagy, and address proteins to lysosomal degradation via endosomal microautophagy. USP19 has recently emerged as the protein responsible for the unconventional secretion of misfolded proteins including Parkinson's disease-associated protein α-synuclein. Despite mounting evidence that USP19 plays crucial roles in several biological processes, the underlying mechanisms are unclear due to lack of information on the physiological substrates of USP19. Herein, we used high-resolution quantitative proteomics to analyze changes in the secretome and cell proteome induced by the loss of USP19 to identify proteins whose secretion or turnover is regulated by USP19. We found that ablation of USP19 induced significant proteomic alterations both in and out of the cell. Loss of USP19 impaired the release of several lysosomal proteins, including legumain (LGMN) and several cathepsins. In order to understand the underlaying mechanism, we dissected the USP19-regulated secretion of LGMN in several cell types. We found that LGMN was not a deubiquitinase substrate of USP19 and that its USP19-dependent release did not require their direct interaction. LGMN secretion occurred by a mechanism that involved the Golgi apparatus, autophagosome formation, and lysosome function. This mechanism resembled the recently described "lysosomal exocytosis," by which lysosomal hydrolases are secreted, when ubiquitination of p62 is increased in cells lacking deubiquitinases such as USP15 and USP17. In conclusion, our proteomic characterization of USP19 has identified a collection of proteins in the secretome and within the cell that are regulated by USP19, which link USP19 to the secretion of lysosomal proteins, including LGMN.

Verified
Journal Article
Open access
PDF file
ACAlessia Ciringione
Alessia Ciringione
MMMarina Marozzi
Marina Marozzi
SBSilvana Belletti
Silvana Belletti
MPMargot Lo Pinto
Margot Lo Pinto
Simone D. ScilabraSimone D. Scilabra
Simone D. Scilabra
FRFederica Rizzi
Federica Rizzi
Metastatic breast cancer (BC) remains a major clinical challenge, and identifying molecular mechanisms driving tumor cell migration and invasion is critical to develop effective therapeutic strategies. Clusterin (CLU), a secreted chaperone-like protein, is upregulated in BC and metastatic tissue; however, its functional contribution to tumor aggressiveness remains unclear. Here, we silenced CLU by siRNA in two BC cell lines with distinct aggressiveness and examined its impact on migration, invasion, and associated signaling pathways. Following CLU silencing, cell migration and invasion were assessed using transwell assays. Cytoskeletal organization was evaluated by F-actin staining, while downstream signaling pathways were analyzed by RT-PCR, Western blotting, and Rho GTPase pull-down. A comparative proteomic analysis was performed in CLU-expressing and CLU-silenced MDA-MB-231 cells. CLU knockdown significantly reduced migration and invasion in MDA-MB-231, concomitantly with loss of F-actin-rich membrane protrusions, reduced expression of MMP9, COL1A1, and COL4A1, and decreased activation of Akt, NF-κB, and RhoA. Proteomic profiling revealed extensive remodeling of pathways involved in cell adhesion, cytoskeletal dynamics, and extracellular matrix interactions. Differently, no or very mild effects were observed in CLU-silenced MCF-7 cells. These findings identify CLU as an upstream regulator of a pro-metastatic adhesion–cytoskeleton signaling in BC, selectively operative in EMT-engaged, basal-like cells, highlighting the importance of patient stratification for CLU-targeted therapeutic strategies.

10 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
OROriana Lo Re
Oriana Lo Re
CCChristian Corti
Christian Corti
LCLucia Cerrito
Lucia Cerrito
ECEleonora Cesari
Eleonora Cesari
ECElisabetta Creta
Elisabetta Creta
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
Patient-derived organoids (PDOs) have emerged as promising preclinical models for studying tumor biology and testing therapeutic strategies in oncology. These three-dimensional culture systems retain key histological, genetic, and functional characteristics of the original tumors, offering a unique opportunity to advance personalized medicine approaches in liver cancer. In this study, we present the methodological framework and preliminary findings of a prospective study aimed at generating and characterizing PDOs from patients with hepatocellular carcinoma (HCC) undergoing surgical resection. Tumor specimens were processed using an optimized protocol for organoid derivation, expansion, and cryopreservation. We evaluated the success rate of organoid establishment and the histo-molecular fidelity to the parental tumor. These early results demonstrate promising engraftment efficiency and maintenance of tumor-specific markers across passages. Our work highlights the potential of PDOs as a reliable and scalable platform for translational research in HCC, setting the stage for future applications in drug screening and biomarker discovery.

26 May 2026 in Plant Physiology and Biochemistry
Verified
Journal Article
Open access
VRValentina Ricciardi
Valentina Ricciardi
GPGuglielmo Puccio
Guglielmo Puccio
LALoredana Abbate
Loredana Abbate
TFTeresa Faddetta
Teresa Faddetta
MPMargot Lo Pinto
Margot Lo Pinto
VCVincenzo Cavalieri
Vincenzo Cavalieri
The increasing demand for sustainable agricultural practices has highlighted the potential of Plant Growth-Promoting Bacteria (PGPB) as eco-friendly tools to enhance crop productivity while minimizing environmental impact. Among PGPBs, members of the Actinomycetota phylum (formerly known as actinobacteria), and particularly Streptomyces violaceoruber, have emerged as promising candidates due to their ability to produce bioactive metabolites, promote plant growth, and modulate plant physiological responses. In this work, we investigated the effects of S. violaceoruber on tomato (Solanum lycopersicum) in vitro - grown seedlings using an integrated phenotypic, volatilomic, transcriptomic, and epigenetic approach. Seedlings were analyzed at seven (T1) and fifteen days (T2) post-inoculation with S. violaceoruber. Phenotypic assessment of inoculated seedlings revealed no significant alterations in shoot length or biomass, while a remarkable increase in seedling root diameter and the formation of aerial roots was observed. Transcriptomic analyses showed substantial transcriptional reprogramming, with a greater number of differentially expressed genes (DEGs) at T1, in particular involved in the regulation of biological processes, metabolic pathways, and responses to external stimuli, such as light. Co-expression network analysis of four root-associated bait genes further confirmed that these pathways are primary targets of S. violaceoruber effects. Epigenetic profiling of treated plant roots revealed an increase in global DNA methylation (5-methylcytosine) levels, along with a significant enrichment of histone post-translational modifications associated with permissive chromatin at the bait gene loci. Overall, S. violaceoruber inoculation induced notable molecular and developmental changes in tomato seedlings, reinforcing its potential as a sustainable biofertilizer. These findings provide new insights into PGPB-plant interactions and contribute to the development of environmentally-friendly strategies for crop improvement.